Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening

Hip Arthrosis Clinical Trial

Official title:

Could the Intra-operative Clodronate Rinsing Improve the Integration of the Femoral Stem in a Prospective, Double-blinded, Randomized, Placebo-controlled Clinical RSA-study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03803839
• Other study ID #: Ei tiedossa
• Status: Completed
• Phase: Early Phase 1
• Start date: March 26, 2004
• Est. completion date: March 12, 2014

Study information

• Verified date: January 2019
• Source: University of Oulu
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Periprosthetic bone-loss after total hip arthroplasty (THA), detected as an early migration of the prosthesis, may predict later loosening. The investigators hypothesized that by reducing bone resorption after THA with bisphosphonates, it might be possible to achieve better early fixation of the implant.

Nineteen patients suffering arthrosis were recruited to a prospective, double-blinded, randomized, placebo-controlled clinical pilot trial. Patients were operated with an uncemented Bimetric stem with tantalum markers, the acetabular cup and liner were chosen by the surgeon. The femoral proximal intramedullary canal was rinsed with 1mM (millimole) clodronate, that was done by adding the clodronate to the 1000 ml 0.9% NaCl (sodium chloride) in nine patients and rinsing solution was the pure 0.9% NaCl for 10 patients. These rinsing packages were labeled only with the code from the pharmacy of the hospital. These patients were followed for two years using radiostereometric analysis (RSA), dual energy x-ray absorptiometry (DXA) and the Harris hip score (HHS).

The purpose of the investigator's study was to examine whether the local intraoperative administration of clodronate could reduce periprosthetic bone loss and further stem migration after primary THA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: March 12, 2014
• Est. primary completion date: March 12, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 73 Years

Eligibility

Inclusion Criteria:

• hip arthrosis and

• a primary THA was planned

Exclusion Criteria:

• renal insufficiency

• hypercalcemia

• malignant tumors

• contemporaneously treatment with another bisphosphonate or aminoglycoside

Related Conditions & MeSH terms

• Hip Arthrosis
• Joint Diseases
• Osteoarthritis, Hip

Intervention

Drug:
• Clodronate

• Saline

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Oulu

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Migration of femoral stem	Subsidence and vertical movement of the femoral stem (scale micrometers), x-, y- and z-translations. Parameters were measured using RSA-methods and the scaling is linear. Lower values represent a better outcome.	0 to 24 months
Other	The maximal (MTPM) maximal total point motion	The maximal MTPM value after 3 months when the expected integration of stem should have happened. Lower values represent a better outcome.	3 to 24 months
Other	Correlation between baseline BMD and the maximal MTPM	This parameters summarize the BMD and RSA values together. The investigators have planned it to evaluate the correlation between the quality of periprosthetic bone in baseline and the migration of femoral stem during 2 years follow-up period between the study groups.	BMD (0 month) - the maximal MTPM 3 to 24 months
Other	Harris Hip Score (HHS)	Harris Hip Score (HHS) is a clinician-based outcome measure, health status scale, that is frequently used to measure the outcome of total hip arthroplasty. It is measured by questionnaire that give points from 0 to 100. Higher values represent a better outcome.	0 to 24 months
Primary	Maximal total point motion (MTPM) - migration of the femoral stem	It represents the length of the translation vector of the point in a rigid body that has the greatest motion. It can only have positive values, and is not normally distributed. The reason for using MTPM is that in many cases, motion implies a biological effect of some kind and this effect is liable to be greatest at the point of maximum motion. The parameter has been measured by RSA-methods, which is an accurate method of determining the migration and wear of orthopaedic implants: it determine the precise location of two distinct objects relative to each other in three dimension such as the relative position of the femoral component and the proximal femur. In radiostereometric analysis the position in space of the original object is reconstructed from a two dimensional x-ray film using tantalum beads. Movement between segments is then calculated by localizing each segment in a coordinate system. Lower values represent a better outcome.	0 to 24 months
Secondary	Bone mineral density (BMD) in 7 Gruen zones	BMD was measured by dual-energy X-ray absorptiometry, DXA. In clinical use, precision errors are < 5 %. To evaluate the horizontal linear distribution of the BMD, seven Gruen zones, peri-prosthetic sub-regions of interest, ROI (region of interest) were calculated by the software on the anteroposterior view of the proximal femur. The value of BMD is g/cm2 and it estimates the strength of the bone. Higher values/lesser decrease in values represent a better outcome.	0 to 24 months